Development of antivirals against influenza

Bibliography

• STUART-HARRIS CH, SCHILD GC, OXFORD JS: Influenza: The Viruses and the Disease. Edward Arnold, New York (1985).
   Google Scholar
• CIMONS M: Aerosol influenza vaccine shows promise. ASM News (1997) 10:533–534.
   Google Scholar
• Update: influenza activity -United States, 1995-96 sea-son (reprinted from MMWR, vol 45, pg 134-136,1996). JAMA (1996) 275:677.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG: Influenza in the Hderly. J. Ger. Drug Ther. (1995) 10:5–23.
   Google Scholar
• PARVIN JD, MOSCONA A, PAN WT, LEIDER JM, PALESE P: Measurement of the mutation rates of animal viruses: influenza virus and poliovirus type 1. j Virol. (1986) 59:377–383.
   PubMed Web of Science ®Google Scholar
• SUAREZ-LOPEZ P, ORTIN J: An estimation of the nucleo-tide substitution rate at defined positions in the influ-enza virus haemagglutinin gene. J Gen. Virol. (1994) 75:389–393.
   PubMed Web of Science ®Google Scholar
• STEINHAUER DA, HOLLAND JJ: Rapid Evolution of RNA viruses. Ann. Rev. Microbiol. (1987) 41:409–433.
   PubMed Web of Science ®Google Scholar
• FANG R, MIN JOU W, HUYLEBROECK D, DEVOS R, FIERS W: Complete structure of A/duck/Ukraine/63 influenza hemagglutinin gene: animal virus as pro-genitor of human H3 Hong Kong 1968 influenza hemagglutinin. Cell (1981) 25:315–323.
   PubMed Web of Science ®Google Scholar
• WEBSTER RG, KAWAOKA Y: Influenza - an emerging and r e-emerging disease. Semin. Virol. (1994) 5:103–111.
   Google Scholar
• COUCH RB: Advances in influenza virus vaccine re-search. Ann. NY Acad. Sci. (1993) 685:803–812.
   PubMed Web of Science ®Google Scholar
• LAMB RA, CHOPPIN PW: The gene structure and replica-tion of influenza virus. Ann. Rev. Biochem. (1983) 52:467–506.
   PubMed Web of Science ®Google Scholar
• RICHARDSON JC, AKKINA RK: N52 protein of influenzavirus is found in purified virus. Arch. Virol. (1991) 116:69–80.
   PubMed Web of Science ®Google Scholar
• YASUDA J, NAKADA S, KATO A, TOYODA T, ISHIHAMA A:Molecular assembly of influenza virus: association of the NS2 protein with virion matrix. Virology (1983) 196:249–255.
   Google Scholar
• WHITE JM: Membrane fusion. Science (1992) 258:917–924.
   PubMed Web of Science ®Google Scholar
• STEINHAUER DA, SAUTER NK, SKEHEL JJ, WILEY DC: Re-ceptor binding and cell entry by influenza viruses. Semin. Virol. (1992) 3:91–100.
   Google Scholar
• STEGMANN T, HELENIUS A: Influenza virus fusion: from models toward a mechanism. In: Viral Fusion Mecha-nisms. Bentz J (Ed.), CRC Press, Boca Raton, Florida (1993):89–111.
   Google Scholar
• WILSON IA, SKEHEL JJ, WILEY DC: Structure of the hae-magglutinin membrane glycoprotein of influenza vi-rus at 3° A resolution. Nature (1981) 289:366–373.
   PubMed Web of Science ®Google Scholar
• •Initial structure determination of the haemagglutinin molecule.
   Google Scholar
• LAZAROWITZ SG, CHOPPIN PW: Enhancement of the in-fectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypep tide. Virology (1975) 68:440–454.
   PubMed Web of Science ®Google Scholar
• WEIS W, BROWN JH, CUSACK S et al.: Structure of the in-fluenza virus haemagglutinin complexed with its re-ceptor, sialic acid. Nature (1988) 333:426–431.
   PubMed Web of Science ®Google Scholar
• HELENIUS A: Unpacking the incoming influenza virus. Cell (1992) 69:577–578.
   PubMed Web of Science ®Google Scholar
• WHITE JM: Viral and cellular membrane fusion pro-teins. Ann. Rev. Physiol. (1990) 52:675–697.
   PubMed Web of Science ®Google Scholar
• GAUDIN Y, RUIGROK RWH, BRUNNER J: Low pH in-duced conformational changes in viral fusion pro-teins: implicatons for the fusion mechanism. J. Gen. Virol. (1995) 76:1541–1556.
   PubMed Web of Science ®Google Scholar
• CARR CM, KIM PS: A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (1993) 73:823–832.
   PubMed Web of Science ®Google Scholar
• •Elegant study which generates a proposal for a mechanism by which the HA undergoes a conformational change which results in virus-cell membrane fusion.
   Google Scholar
• DURRER P, GALLI C, HOENKE S et al: HE-induced mem- brane insertion of influenza virus hemagglutinin in-volves the HA2 amino-terminal fusion peptide but not the coiled coil region. J Biol. Chem. (1996) 271 :13417–13421.
   PubMed Web of Science ®Google Scholar
• SUGRUE RJ, HAY AJ: Structural characteristics of the M2 protein of the influenza A viruses: evidence that it forms a tetrameric channel. Virology(1991) 180:617–624.
   PubMed Web of Science ®Google Scholar
• HOLSINGER LJ, LAMB RA: Influenza virus M2 integral membrane protein is a momodimer stabilized by for-mation of disulfide bonds. Virology (1991) 183:32–43.
   PubMed Web of Science ®Google Scholar
• HOLSINGER LI NICHANI D, PINTO LH, LAMB RA: Influ-enza A virus M2 ion channel protein: a structure func-tion analysis. J Viro/. (1994) 68:1551–1563.
   PubMed Web of Science ®Google Scholar
• PINTO LH, HOLSINGER LI LAMB RA: Influenza virus M2 protein has ion channel activity. Cell (1992) 69:517–528.
   PubMed Web of Science ®Google Scholar
• •Elucidates the mechanism of viral uncoating.
   Google Scholar
• ZHIRNOV OP: Isolation of matrix protein M1 from in-fluenza viruses by acid-dependent extraction with nonionic detergent. Virology (1992) 186:324–330.
   PubMed Web of Science ®Google Scholar
• SUGRUE RJ, BAHADUR G, ZAMBON MC et al.: Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J (1990) 9:3469–3476.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI K, LAMB RA: Influenza virus M2 protein ion channel activity stabilizes the native form of fowl plague virus hemagglutinin during intracellular trans-port. J. Viro/. (1994) 68:911–919.
   PubMed Web of Science ®Google Scholar
• OHUCHI M, CRAMER A, VEY M et al.: Rescue of vector-expressed fowl plague virus hemagglutinin in biologi-cally active form by acidotropic agents and expressed M2 M2 protein. J Viro/. (1994) 68:920–926.
   PubMed Web of Science ®Google Scholar
• ZVONNARJEV AY, GHENDON, Z: Influence of mem-brane (M) protein on influenza A virus virion tran - scriptase activity in vitro and its susceptibility to rimantadine. j Viro/. (1980) 33:583–586.
   PubMed Web of Science ®Google Scholar
• YE ZP, BAYLOR NW, WAGNER RR: Transcription - inhi-bition and RNA - binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Viro/. (1989) 63:3586–3594.
   PubMed Web of Science ®Google Scholar
• WAKEFIELD L, BROWNLEE GG: RNA-binding properties of influenza A virus matrix protein Ml. Nucleic Acids Res. (1989) 17:8569–8580.
   PubMed Web of Science ®Google Scholar
• MARTIN K, HELENIUS A: Nuclear transport of influenza ribonucleoproteins: the viral matrix protein (M1) pro-motes export and inhibits import. Cell (1991) 67:117–130.
   PubMed Web of Science ®Google Scholar
• JIN H, LESER GP, ZHANG J, LAMB RA: Influenza virus he-magglutinin and neuraminidase cytoplasmic tails con-trol particle shape. EMBO J (1997) 16:1236–1247.
   PubMed Web of Science ®Google Scholar
• SHA B, LUO M: Structure of a bifunctional membrane-RNA binding protein, influenza virus matrix protein M1. Nat. Struct. Biol. (1997) 4:239–244.
   PubMedGoogle Scholar
• HSU M-T, PARVIN JD, GUPTA S, KRYSTAL M, PALESE P: Genomic RNAs of influenza viruses are held in a circu-lar conformationin virions and in infected cells by a terminal panhandle. Proc. Nail. Acad. Sci. USA (1987) 84:8140–8144.
   PubMed Web of Science ®Google Scholar
• HONDA A, MUKAIGAWA J, YOKOIYAMA A et al.: Purifi-cation and molecular structure of RNA polymerase from Influenza virus A/PR8. j Biochem. (1990) 107:624–628.
   PubMed Web of Science ®Google Scholar
• ISHIHAMA A, NAGATA K: Viral RNA polymerases. CRCCritical Reviews in Biochem. (1988) 23:27–76.
   PubMed Web of Science ®Google Scholar
• KRUG RM, ALONSO-CAPLEN FV, JULKUNEN I, KATZE MG:Expression and replication of the influenza virus ge-nome. In: The Influenza Viruses Krug RM (Ed.), Plenum Press, New York (1989) 89–152.
   Google Scholar
• BRAAM J, ULMANEN I, KRUG R.M: Molecular model of aeukaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell (1983) 34:609–618.
   Google Scholar
• •Seminal work describing various functions of the influenza polymerase.
   Google Scholar
• KRUG RM: Priming of influenza viral RNA transcription by capped heterologous RNAs. Curr. Top. Microbiol. Im-munol. (1981) 93:125–150.
   PubMedGoogle Scholar
• PLOTCH SJ, BOULOY M, ULMANEN I, KRUG RM: Aunique cap (m7GppXm)-dependent influenza virion endonu-clease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell (1981) 23 :847–858.
   PubMed Web of Science ®Google Scholar
• BACHI T, GERHARD W, LINDERMAN J, MUHLETHALER K:Morphogenesis of influenza A virus in Ehrlich ascites tumor cells as revealed by thin sectioning and freeze etching. J Virol. (1969) 4:769–776.
   PubMed Web of Science ®Google Scholar
• PALESE P, SCHULMAN JL, BODO G, MEINDL P: Inhibitionof influenza and parainfluenza virus replication in tis-sue culture by 2-deoxy-2,3-dehydro-N-trifluoro-acetylneuraminic acid (FANA). Virology (1974) 59:490–498.
   PubMed Web of Science ®Google Scholar
• GOTTSCHALK A: The specific enzyme of influenza vi-rus and Vibrio cholerae. Biochem. Biophys. Acta (1957) 23:645–646.
   PubMed Web of Science ®Google Scholar
• TOMINACK RLH: Rimantadine hydrochloride and amantadine hydrochloride use in influenza Avirus in-fections. Infect. Dis. Clin. North. Am. (1987) 1:459–478.
   PubMedGoogle Scholar
• DOUGLAS RG Jr: Drug therapy: prophylaxis and treat-ment of influenza. New Engl. J. Med. (1990) 322 :443–450.
   PubMed Web of Science ®Google Scholar
• GOMOLIN IH, LEIB HB, ARDEN NH, SHERMAN FT: Con-trol of influenza outbreaks in the nursinghome: guide-lines for diagnosis and management. J. Am. Geriatr. Soc. (1995) 43:71–74.
   PubMed Web of Science ®Google Scholar
• HAYDEN F, BELSHE RB, CLOVER RD et al.: Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. New Engl. J Med. (1989) 321:1696–1702.
   PubMed Web of Science ®Google Scholar
• BETTS RF: Resistance to rimantadine and amantadine. Curr. Opin. Infect. Dis. (1991) 4:804–808.
   Web of Science ®Google Scholar
• HAYDEN FG, SPERBER SJ, BELSHE RB et al.: Recovery of drug-resistant influenza Avirus during therapeutic use of rimantadine. Antimicrob. Agents and Chemother. (1991) 35:1741–1747.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG, COUCH RB: Clinical and epidemiological importance of influenza A viruses resistant to aman-tadine and rimandatine. Med. Vim]. (1992) 2:89–96.
   Google Scholar
• HAYDEN FG, HAY AJ: Emergence and transmission of influenza Aviruses resistant to amantadine and riman-tadine. Curr. Top. Microbiol. Immunol. (Genet. Diversity RNA Viruses) (1992) 176:119–130.
   PubMed Web of Science ®Google Scholar
• MAST EE, HARMON MW, GRAVENSTEIN S et al.: Emer-gence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of in-fluenza A (H3N2). Arm J Epidemiol. (1991) 134:988–997.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG: Combination antiviral therapy for respi-ratory virus infections. Antivir. Res. (1996) 29:45–48.
   PubMed Web of Science ®Google Scholar
• BETTS RF: Potential agents in the treatment of influ-enza. Curr. Opin. Infect. Dis. (1992) 5:811–815.
   Web of Science ®Google Scholar
• STOOF JC, BOOIJ J, DRUKARCH B: Arnantadine as N-methyl aspartic acid receptor antagonist: new possi-bilities for therapeutic applications? Clin. Neurol. Neu-rosurg. (1992) 94 (Suppl.):4–6.
   Google Scholar
• HAYDEN FG, HOFFMAN HE, SPYKER DA: Differences inside effects of amantadine hydrochloride and riman-tadine hydrochloride relate to differences in pharma-cokinetics. Antimicrob. Agents Chemother. (1983) 23:458–464.
   PubMed Web of Science ®Google Scholar
• OBESO JA, MARTINEZ-LAGE JM: In: The Handbook of Park-inson's Disease. Koller WC (Ed.), Marcel Dekker, New York (1987):312–316.
   Google Scholar
• MONTO AS, OHMIT SE, HORNBUCKLE K, PEARCE CL: Safety and efficacy of long-term use of rimantidine for prophylaxis of type Ainfluenza in nursing Homes. An-timicrob. Agents Chemother. (1995) 39:2224–2228.
   PubMedGoogle Scholar
• BRADY MT, SEARS SD, PACINI DL eta].: Safety and pro-phylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob. Agents Che-mother. (1990) 34:1633–1636.
   Google Scholar
• HAY AJ: Potential targets and actions of antiviral agents against influenza viruses. Chem. Scr. (1986) 26:77–81.
   Google Scholar
• HAY AJ: The action of adaman tamin es against influ-enza A viruses: inhibition of the M2 ion channel pro-tein. Semin. Virol. (1992) 3:21–30.
   Google Scholar
• HAY AJ, WOLSTENHOLME, AJ, SKEHEL JJ, SMITH MH: Themolecular basis of the specific anti-influenza action of amantadine. EMBO J (1985) 4:3021–3024.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MA, LAMB RA: Determination of the orienta-tion of an integral membrane protein and sites of gly-cosylation by oligonucleotide-directed mutagenesis: influenza B virus NB glycoprotein lacks a cleavable sig-nal sequence and has an ex tracellular NY12-terminal region. Mol. Cell Biol. (1986) 6:4317–4328.
   PubMed Web of Science ®Google Scholar
• LAMB RA, PINTO LH: Do Vpu and Vpr of human immu-nodeficiency virus type 1 and NB of influenza B virus have ion channel activities in the viral life cycles? Virol-ogy (1997) 229:1–11.
   PubMed Web of Science ®Google Scholar
• SANSOM MSP, KERR ID: Influenza virus M2 protein: a molecular modelling study of the ion channel. Protein Eng. (1993) 6:65–74.
   PubMedGoogle Scholar
• PINTO LH, DIECKMANN GR, GANDHI CS eta].: A func-tionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion se-lectivity. Proc. Natl. Acad. Sci. USA (1997) 94:11301–11306.
   Google Scholar
• SANSOM MS, KERR ID, SMITH GR, SON HS: The influenza A virus M2 channel: a molecular modeling and simula-tion study. Viro/ogy (1997) 233:163–173.
   PubMed Web of Science ®Google Scholar
• WANG C, LAMB RA, PINTO LH: Activation of the M(2) ion channel of influenza virus: a role for the transmem-brane domain histidine residue. Biophys. J. (1995) 6 9:1363–1371.
   Google Scholar
• KURTZ S, LUO GX, HAHNENBERGER KM eta].: Growth impairment resulting from expression of influenza vi-rus M2 protein in Saccharomyces cerevisiae: identifi-cation of a novel inhibitor of influenza virus. Antimicro. Agents Chemother. (1995) 39:2204–2209.
   Google Scholar
• HAHNENBERGER KM, KRYSTAL M, ESPOSITO K, TANG W, KURTZ S: Use of microphysiometry for analysis of het-erologous ion channels expressed in yeast. Nature Bio-technol. (1996) 14:880–883.
   PubMed Web of Science ®Google Scholar
• TU Q, PINTO LH, LUO GX et al: Characterization of inhi-bition of M(2) ion channel activity by BL-1743, an in-hibitor of influenza Avirus. Virof (1996) 70:4246–4252.
   PubMed Web of Science ®Google Scholar
• LIN TI, HEIDER H, SCHROEDER C: Different modes of in-hibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influ-enza virus M2 proton channel protein. J Gen. Virol. (1997) 78:767–774.
   PubMed Web of Science ®Google Scholar
• EDMOND JD, JOHNSTON RG, KIDD D, RYLANCE HJ, SOM-ERVILLE RG: The inhibition of neuraminidase and an-tiviral action. Br. J. Pharmac. Chemother. (1966) 27:415–426.
   PubMed Web of Science ®Google Scholar
• VARGHESE JN, LAVER WG, COLMAN PM: Structure of theinfluenza virus glycoprotein antigen neuraminidase at 2.9 Ã resolution. Nature (1983) 303 :35–40.
   PubMed Web of Science ®Google Scholar
• •Initial structure determination of the viral neuraminidase.
   Google Scholar
• COLMAN PM: Crystallographic studies of influenza vi-rus neuraminidase and implications for new anti-influenza drugs. [Spec. Publ.] R. Soc. Chem. (Recent Ad-vances in the Chemistry of anti-infective Agents) (1993) 119:348–355.
   Google Scholar
• VARGHESE JN, MCKIMM-BRESCHKIN JL, CALDWELL JB,KORTT AA, COLMAN PM: The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins (1992) 14:327–332.
   PubMed Web of Science ®Google Scholar
• •Structural determination of neuraminidase with sialic acid bound in the active site.
   Google Scholar
• BURMEISTER WP, RUIGROK RWH, CUSACK S: The 2.2 Ãresolution crystal structure of influenza B neuramini-dase and its complex with sialic acid. EMBO (1992) 11:49–56.
   Google Scholar
• JANAKIRAMAN M, WHITE CL, LAVER WG, AIR GM, LUO M:Structure of influenza virus neuraminidase B/Ize/40 complex ed with sialic acid and a dehydro analog at 1.8-A resolution: implication for the catalytic mecha-nism. Biochemistry (1994) 33:8172–8179.
   Google Scholar
• VON ITZSTEIN M, WU W-Y, KOK GB eta].: Rational de- sign of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 363:418–423.
   Google Scholar
• •Initial description of rational drug design and characterisa-tion of GG-167.
   Google Scholar
• VON ITZSTEIN M, BARRY JB, CHONG AKJ: The develop-ment of potential anti-influenza drugs. Cum Opin. Ther. Patents (1993) 3:1755–1762.
   Google Scholar
• MEINDL P, BODO G, PALESE P, SCHULMAN J, TUPPY H: Inhibition of neuramindase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virol-ogy (1974) 58:457–463.
   PubMed Web of Science ®Google Scholar
• BAMFORD MJ: Neuraminidase inhibitors as potential anti-influenza drugs. J. Enzyme Inhib. (1995) 10:1–16.
   Web of Science ®Google Scholar
• WOODS JM, BETHELL RC, COATES JAV et al.: 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylne-uraminic acid is a highly effective inhibitor both of sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. (1993) 37:1473–1479.
   PubMed Web of Science ®Google Scholar
• GUBAREVA LV, PENN CR, WEBSTER RG: Inhibition of replication of avian influenza viruses by the neu-raminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology (1995) 212:323–330.
   PubMed Web of Science ®Google Scholar
• THOMAS GP, FORSYTH M, PENN CR, MCCAULEY JW: In-hibition of the growth of influenza viruses in vitro by 4 -guanidino-2,4 -dideoxy-2, 3 -dehydro-N-acetylneuraminic acid. Antiviral Res. (1994) 24:351–356.
   PubMed Web of Science ®Google Scholar
• HOLZER CT, VON ITZSTEIN M, JIN B eta].: Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-ac-etylneuraminic acid modified at the C-4 position. Gly-coconjugate J. (1993) 10:40–44.
   Google Scholar
• HAYDEN FG, ROLLINS BS, MADREN LK: Anti-influenza virus activity of the neuraminidase inhibitor 4-g-uanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res. (1994) 25:123–131.
   PubMed Web of Science ®Google Scholar
• MCKIMM-BRESCHKIN JL, BUCK TJ, SAHASRABUDHE A et al.: Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-am in o -Neu5 Ac2 en and 4 -g-uan idin o -Neu5 Ac2 en . Anti-microb. Agents Chemother. (1996) 40:40–46.
   PubMed Web of Science ®Google Scholar
• STASCHKE KA, COLACINO JM, BAXTER AJ eta].: Molecu-lar basis for the resistance of influenza viruses to 4-g-uanidino-Neu5Ac2en. Virology (1995) 214:642–646.
   Google Scholar
• BUCK TJ, TIONG T, SAHASRABUDHE A eta].: Generation and characterization of an influenza virus neuramini-dase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology (1995) 214:475–484.
   Google Scholar
• MCKIMM-BRESCHKIN JL, MCDONALD M, BUCK TJ, COL-MAN PM: Mutation in the influenza virus neuramini-dase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology (1996) 225:240–242.
   PubMed Web of Science ®Google Scholar
• GUBAREVA LV, BETHELL R, HART GJ eta].: Characteriza-tion of mutants of influenza A virus selected with the neuraminidase inhibitor 4-g-uanidino-Neu5Ac2en. Virol. (1996) 70:1818–1827.
   Google Scholar
• GUBAREVA LV, ROBINSON MJ, BETHELL RC, WEBSTER RG: Catalytic and framework mutations in the neu-raminidase active site of influenza viruses that are re-sistant to 4-guanidino-Neu5Ac2en. J. Virof (1997) 71:3385–3390.
   PubMed Web of Science ®Google Scholar
• RYAN DM, TICEHURST J, DEMPSEY MH, PENN CR: Inhibi-tion of influenza virus replication in mice by GG167 (4 -guanidin o -2, 4 -dideoxy-2, 3 -dehydr o-N-acetylneuraminic acid) is consistent with ex tracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. (1994) 38:2270–2275.
   PubMed Web of Science ®Google Scholar
• RYAN DM, TICEHURST J, DEMPSEY MH: GG-167 (4-guanidino-2,4-dideoxy-2,3-dehydro -N-acetylne-uraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob. Agents Chemother. (1995) 39:2583–2584.
   PubMed Web of Science ®Google Scholar
• EFTHYMIOPOULOS C, BARRINGTON P, PATEL J et al.: Pharmacokinetics of the neuraminidase inhibitor 4-g-uanidino Neu5Ac2en (GG167) following intranasal and inhaled administration in man. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. (1994):H–70.
   Google Scholar
• HAYDEN F, LOBO M, ESINHART J, HUSSE E: Efficacy of 4-g-uanidino Neu5Ac2en in experimental human influ-enza A virus infection. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. (1994):H–35.
   Google Scholar
• HAYDEN F, TREANER JJ, ESINHART J, EASON CU: Twice daily intranasal GG167 for experimental influenza A. Antiviral Res. (1995) 26:140.
   Google Scholar
• HAYDEN FG, OSTERHAUS AD, TREANOR JJ eta].: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New Engl. J. Med. (1997) 337:874–880.
   Google Scholar
• •Results of Phase III clinical trial of GG-167.
   Google Scholar
• GUBAREVA LV, BRENNER MK, WEBSTER RG: Molecular characterization of influenza B virus from a patient af-ter treatment with a neuraminidase targeted antiviral. American Society for Virology Meeting Abstracts (1997): W6–9.
   Google Scholar
• SCHILLING M, POVINELLI L, KRAUSE P, GRAVENSTEIN M et al.: Efficacy of zanamir for chemoprophylaxis of nursing home influenza A outbreaks. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. (1997):H–92.
   Google Scholar
• SOLLIS SL, SMITH PW, HOWES PD, CHERRY PC, BETHELL RC: Novel inhibitors of influenza sialidase related to GG167 - synthesis of 4-amino and g-uanidino-4H-pyran-2-carboxylic acid-6-propylamides; selective in-hibitors of influenza A virus sialidase. Bioorg. Med. Chem. Lett. (1996) 6:1805–1808.
   Web of Science ®Google Scholar
• KIM CU, LEW W, WILLIAMS MA et al.: Influenza neu-raminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: de-sign, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activ-ity. J. Arm Chem. Soc. (1997) 119:681–690.
   PubMed Web of Science ®Google Scholar
• •Description and characterisation of GS 4071 and GS 4104.
   Google Scholar
• EISENBERG EJ, BIDGOOD A, CUNDY KC: Penetration of GS 4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral ad-ministration of the prodrug GS 4104. Antimicrob. Agents Chemother. (1997) 41:1949–1952.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG, LOBO M, TREANER JJ, MILLER M, MILLS RG: Efficacy and tolerability of oral GS 4104 for early treat-ment of experimental influenza in humans. 37th In-terscience Conference on Antimicrobial Agents and Chemotherapy. (1997):LB–26.
   Google Scholar
• MCKIMM-BRESCHKIN JL: Personal communication.
   Google Scholar
• HAYDEN FS, ROLLINS BS: In vitro activity of the neu-raminidase inhibitor GS 4071 against influenza vi-ruses. Antiviral Res. (1997) 34:A86.
   Google Scholar
• SAUTER NK, BEDNARSKI MD, WURZBURG BA eta].: He-magglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic reso-nance study. Biochemistry (1989) 28:8388–8396.
   Google Scholar
• TOOGOOD PL, GALLIKER PK, GLICK GD, KNOWLES JR: Monovalent sialosides that bind tightly to influenza A virus. J. Med. Chem. (1991) 34:3138–3140.
   PubMed Web of Science ®Google Scholar
• WATOWICH SJ, SKEHEL JJ, WILEY DC: Crystal structures of influenza virus hemagglutinin in complex with high-affinity receptor analogs. Structure (1994) 2:719–731.
   PubMed Web of Science ®Google Scholar
• HANAOKA K, PRITCHETT TJ, TAKASAKI S et al.: 4-0-acetyl-N-acetylneuraminic acid in the N-linked carbo-hydrate structures of equine and guinea pig a2-macr-oglobulins, potent inhibitors of influenza virus infection. J. Biol. Chem. (1989) 264:9842–9849.
   PubMed Web of Science ®Google Scholar
• PRITCHETT TJ, PAULSON JC: Basis for the potent inhibi-tion of influenza virus infection by equine and guinea pig a2-macroglobulin. J Biol. Chem. (1989) 264 :9850–9858.
   PubMed Web of Science ®Google Scholar
• WILEY DC, SKEHEL JJ: The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Ann. Rev. Biochem. (1987) 56:365–394.
   PubMed Web of Science ®Google Scholar
• BOYCOTT R, KLENK H-D, OHUCHI M: Cell tropism of in-fluenza virus mediated by hemagglutinin activation at the stage of virus entry. Virology (1994) 203 :313–319.
   PubMed Web of Science ®Google Scholar
• MAZANEC MB, COUDRET CL, FLETCHER DR: Intracellu-lar neutralization of influenza virus by immunoglobu-lin A antihemagglutinin monoclonal antibodies. J. Virol. (1995) 69:1339–1343.
   PubMed Web of Science ®Google Scholar
• KINGERY-WOOD JE, WILLIAMS KW, SIGAL GB, WHITE-SIDES GM: The agglutination of erythrocytes by influ-enza virus is strongly inhibited by liposomes incorporating an analog of sialyl gangliosides. J Am. Chem. Soc. (1992) 114:7303–7305.
   Web of Science ®Google Scholar
• LEES WJ, SPALTENSTEIN A, KINGERY-WOOD JE, WHITE-SIDES GM: Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological systems. J. Med. Chem. (1994) 37:3419–3433.
   PubMed Web of Science ®Google Scholar
• MAMMEN M, DAHMANN G, WHITESIDES GM: Effective inhibitors of hemagglutination by influenza virus syn-thesized from polymers having active ester groups. In-sight into mechanism of inhibition. J. Med. Chem. (1995) 38:4179–4190.
   Web of Science ®Google Scholar
• CHOI SK, MAMMEN M, WHITESIDES GM: Monomeric in-hibitors of influenza neuraminidase enhance the he-magglutination inhibition activities of polyacrylamides presenting multiple C-sialo side groups. Chem. Biol. (1996) 3:97–104.
   PubMed Web of Science ®Google Scholar
• CHOI SK, MAMMEN M, WHITESIDE GM: Generation and in situ evaluation of libraries of poly(acrylic acid) pre-senting sialosides as side chains as polyvalent inhibi-tors of influenza-mediated hemagglutination. J Am. Chem. Soc. (1997) 119:4103–4111.
   Web of Science ®Google Scholar
• BODIAN DL, YAMASAKI RB, BUSWELL RL et al.: Inhibi-tion of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hy-droquinones. Biochemistry (1993) 32:2967–2978.
   PubMed Web of Science ®Google Scholar
• LUO GX, COLONNO R, KRYSTAL M: Characterization of a hemagglutinin-specific inhibitor of influenza A vi-rus. Virology (1996) 226:66–76.
   PubMed Web of Science ®Google Scholar
• LUO GX, TORRI A, HARTE WE et al: Molecular mecha-nism underlying the action of a novel fusion inhibitor of influenza A virus. J Viro/. (1997) 71:4062–4070.
   PubMed Web of Science ®Google Scholar
• HOFFMAN LR, KUNTZ ID, WHITE JM: Structure-based identification of an inducer of the low pH conforma-tional change in the influenza virus hemagglutinin: ir-reversible inhibition of infectivity. J Viro/. (1997) 71:8808–8820.
   PubMed Web of Science ®Google Scholar
• DESJARLAIS RL, SHERIDAN RP, SEIBEL GL et al.: Using shape complementarity as an initial screen in design-ing ligands for a receptor binding site of known three-dimensional structure./ Med. Chem. (1988) 31:722–729.
   PubMed Web of Science ®Google Scholar
• KUNTZ ID, BLANEY JM, OATLEY SJ, LANGRIDGE R, FER-RIN TE: A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. (1982) 161 :269–288.
   PubMed Web of Science ®Google Scholar
• SHOICHET BK, KUNTZ ID: Matching chemistry and shape in molecular docking. Protein Eng. (1993) 6:723–732.
   PubMedGoogle Scholar
• CIANCI C: Manuscript in preparation.
   Google Scholar
• COLACINO J: Personal communication.
   Google Scholar
• KRYSTAL M, ELLIOTT RM, BENZ EW, YOUNG JF, PALESE P: Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc. Natl. Acad. Sci. USA (1982) 79:4800–4804.
   PubMed Web of Science ®Google Scholar
• ULMANEN I, BRONI BA, KRUG RM: Role of two influenza virus core P proteins in recognizing cap 1 structures (m7GpppNrn) on RNAs and in initiating RNA tran-scription. Proc. Nat. Acad. Sci. USA (1981) 78:7355–7359.
   PubMed Web of Science ®Google Scholar
• CIANCI C, TILEY L, KRYSTAL M: Differential activation of the influenza virus polymerase via template RNAbind-ing. j Vim/. (1995) 69:3995–3999.
   Web of Science ®Google Scholar
• TISDALE M, APPLEYARD G, TUTTLE JV eta].: Inibition of influenza A and B viruses by 2'-deoxy-2'-fluororib-osides. Antiviral Chem. Chemother. (1993) 4:281–287.
   Google Scholar
• TISDALE M, ELLIS M, KLUMPP K, COURTS, FORD M: Inhi-bition of influenza virus transcription by 2'-deoxy--2'-fluoroguanosine. Antimicrob. Agents Chemother. (1995) 39:2454–2458.
   PubMed Web of Science ®Google Scholar
• ROLLINS BS, ELKHATIEB AHA, HAYDEN FG: Compara-tive anti-influenza virus vctivity of 2'-deoxy-2'-fluoro-ibosides in vitro. Antiviral Res. (1993) 21:357–368.
   PubMedGoogle Scholar
• JAKEMAN KJ, TISDALE M, RUSSELL S, LEONE A, SWEET C: Efficacy of 2'-deoxy-2'-fluororibosides against influ-enza A and B viruses in ferrets. Antimicrob. Agents Che-mother. (1994) 38:1864–1867.
   PubMed Web of Science ®Google Scholar
• CLOAD PA, HUTCHINSON DW: The inhibition of the RNA polymerase activity of influenza virus A by pyro-phosphate analogues. Nucl. Acids Res. (1983) 11:5621–5628.
   PubMed Web of Science ®Google Scholar
• STRIDH S, DATEMA R: Mode of interference of triso-dium phophonoformate (INN: Foscarnet sodium), with influenza virus mRNA synthesis. Virology (1984) 135:293–296.
   PubMed Web of Science ®Google Scholar
• BECKER BN, SCHULMAN G: Nephrotoxicity of antiviral therapies. Curr. Opin. Nephrol. Hypertens. (1996) 5:375–379.
   PubMedGoogle Scholar
• TOMASSINI J, SELNICK H, DAVIES ME eta].: Inhibition of cap (m7GppplCrn)-dependent endonuclease of influ-enza virus by 4-substituted 2,4-dioxobutanoic Acid Compounds. Antimicrob. Agents Chemother. (1994) 38:2827–2837.
   Google Scholar
• HASTINGS JC, SELNICK H, WOLANSKI B, TOMASSINI JE: Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob. Agents Che-mother. (1996) 40:1304–1307.
   PubMed Web of Science ®Google Scholar
• HENSENS OD, GOETZ MA, LIESCH JM eta": Isolation and structure of flutimide, a novel endonuclease inhibitor of influenza virus. Tet. Lett. (1995) 36:2005–2008.
   Web of Science ®Google Scholar
• TOMASSINI JE, DAVIES ME, HASTINGS JC eta].: A novel antiviral agent which inhibits the endonuclease of in-fluenza viruses. Antimicrob. Agents Chemother. (1996) 40:1189–1193.
   Google Scholar
• CIANCI C, CHUNG TDY, MEANWELL N eta].: Identifica-tion of N-hydroxamic acid and N-hydroxyimide com-pounds that inhibit the influenza virus polymerase. Antivir. Chem. Chemother. (1996) 7:353–360.
   Google Scholar
• SIDWELL RW, ROBINS RK, HILLYARD IW: Ribavirin: an antiviral agent. Pharmacol. Ther. (1979) 6:123–46.
   PubMed Web of Science ®Google Scholar
• STREETER DG, WITKOWSKI JT, KHARE GP eta].: Mech a-nism of action of 1-13-D-ribofuranosy1-1,2,4-triazole-3-carbox amide (virazole), a new broad-spectrum antivi-ral agent. Proc. Nat. Acad. Sci. USA (1973) 70:1174–1178.
   Google Scholar
• TOGO Y: In vitro effect of virazole against influenza vi-ruses. Antimicrob. Agents Chem. (1973) 4:641–642.
   PubMed Web of Science ®Google Scholar
• MCCLUNG HW, KNIGHT V, GILBERT BE eta].: Ribavirin aerosol treatment of influenza B virus infection. JAMA (1983) 249:2671–2674.
   Google Scholar
• SMITH CB, CHARETTE RP, FOX JP, COONEY MK, HALL CE: Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J. Infect. Dis. (1980) 141 :548–554.
   PubMed Web of Science ®Google Scholar
• COLACINO JM, DELONG DC, NELSON JR eta": Evaluation of the anti-influenza virus vctivities of 1,3,4-thiadiazol-2-ylcyanamide (LY-217896) and its sodium salt. Antimicrob. Agents Chemother. (1990) 34:2156–2163.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG, TUNKEL AR, TREANOR JJ et al.: Oral LY-217896 for prevention of experimental influenza A vi-rus infection and illness in humans. Antimicrob. Agents Chemother. (1994) 38:1178–1181.
   PubMed Web of Science ®Google Scholar
• KLENK HD, OHUCHI M, OHUCHI R eta": Proteolytic acti-vation of influenza viruses: substrates and proteases. FEMS Symposium (Molecular Recognition in Host-Parasite Interactions) (1992) 61 :201–209.
   Google Scholar
• ROTT R, KLENK HD, NAGAI Y, TASHIRO M: Influenza vi-ruses, cell enzymes, and pathogenicity. Am. J. Respir. Crit. Care Med. (1995) 152:S16–S19.
   PubMed Web of Science ®Google Scholar
• SOMEYA A, TANAKA N, OKUYAMA A: Inhibition of in-fluenza virus A/WSNreplication by a tryp sin inhibitor, 6-amidino-2-naphthyl p-g-uanidinobenzoate. Biochem. Biophys. Res. Commun. (1990) 169:148–152.
   PubMed Web of Science ®Google Scholar
• SOMEYA A, TANAKA N, OKUYAMA A: Inhibition of in-fluenza virus A/WSNreplication by serine protease in-hibitors and anti-protease antibodies. Antiviral Chem. Chemother. (1994) 5:187–90.
   Web of Science ®Google Scholar
• HAYDEN FG: Combinations of antiviral agents for treatment of influenza virus infections. J. Antimicrob. Chemother. (1986) 18 (Suppl. B):177–183.
   Google Scholar
• BARNET J, DEMPSEY M, TISDALE M eta].: Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during Phase II clinical efficacy trials. 37th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. (1997):H–93.
   Google Scholar
• HITCHCOCK MJM: GS 4104: a new orally administered anti-influenza drug candidate. Intern. Antiviral News (1996) 4:175.
   Google Scholar